Search

Your search keyword '"Lagergren, Jesper"' showing total 22 results
Start Over Author "Lagergren, Jesper" Journal gut
22 results on '"Lagergren, Jesper"'

2. Germline variation in inflammation-related pathways and risk of Barrettʼs oesophagus and oesophageal adenocarcinoma

Author

Buas, Matthew F, He, Qianchuan, Johnson, Lisa G, Onstad, Lynn, Levine, David M, Thrift, Aaron P, Gharahkhani, Puya, Palles, Claire, Lagergren, Jesper, Fitzgerald, Rebecca C, Ye, Weimin, Caldas, Carlos, Bird, Nigel C, Shaheen, Nicholas J, Bernstein, Leslie, Gammon, Marilie D, Wu, Anna H, Hardie, Laura J, Pharoah, Paul D, Liu, Geoffrey, Iyer, Prassad, Corley, Douglas A, Risch, Harvey A, Chow, Wong-Ho, Prenen, Hans, Chegwidden, Laura, Love, Sharon, Attwood, Stephen, Moayyedi, Paul, MacDonald, David, Harrison, Rebecca, Watson, Peter, Barr, Hugh, deCaestecker, John, Tomlinson, Ian, Jankowski, Janusz, Whiteman, David C, MacGregor, Stuart, Vaughan, Thomas L, and Madeleine, Margaret M

Published
2017
Full Text
View/download PDF

5. British Society of Gastroenterology guidelines on the diagnosis and management of Barrettʼs oesophagus

Author

Fitzgerald, Rebecca C, di Pietro, Massimiliano, Ragunath, Krish, Ang, Yeng, Kang, Jin-Yong, Watson, Peter, Trudgill, Nigel, Patel, Praful, Kaye, Philip V, Sanders, Scott, OʼDonovan, Maria, Bird-Lieberman, Elizabeth, Bhandari, Pradeep, Jankowski, Janusz A, Attwood, Stephen, Parsons, Simon L, Loft, Duncan, Lagergren, Jesper, Moayyedi, Paul, Lyratzopoulos, Georgios, and de Caestecker, John

Published
2014
Full Text
View/download PDF

13. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma

Author

Buas, Matthew F, primary, He, Qianchuan, additional, Johnson, Lisa G, additional, Onstad, Lynn, additional, Levine, David M, additional, Thrift, Aaron P, additional, Gharahkhani, Puya, additional, Palles, Claire, additional, Lagergren, Jesper, additional, Fitzgerald, Rebecca C, additional, Ye, Weimin, additional, Caldas, Carlos, additional, Bird, Nigel C, additional, Shaheen, Nicholas J, additional, Bernstein, Leslie, additional, Gammon, Marilie D, additional, Wu, Anna H, additional, Hardie, Laura J, additional, Pharoah, Paul D, additional, Liu, Geoffrey, additional, Iyer, Prassad, additional, Corley, Douglas A, additional, Risch, Harvey A, additional, Chow, Wong-Ho, additional, Prenen, Hans, additional, Chegwidden, Laura, additional, Love, Sharon, additional, Attwood, Stephen, additional, Moayyedi, Paul, additional, MacDonald, David, additional, Harrison, Rebecca, additional, Watson, Peter, additional, Barr, Hugh, additional, deCaestecker, John, additional, Tomlinson, Ian, additional, Jankowski, Janusz, additional, Whiteman, David C, additional, MacGregor, Stuart, additional, Vaughan, Thomas L, additional, and Madeleine, Margaret M, additional

Published
2016
Full Text
View/download PDF

14. Helicobacter pylorieradication treatment and the risk of gastric adenocarcinoma in a Western population

Author

Doorakkers, Eva, Lagergren, Jesper, Engstrand, Lars, and Brusselaers, Nele

Abstract

ObjectiveGastric infection with Helicobacter pyloriis a strong risk factor for non-cardia gastric adenocarcinoma. The aim of this study was to assess whether the risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma decreases after eradication treatment for H. pyloriin a Western population.DesignThis was a nationwide, population-based cohort study in Sweden in 2005–2012. Data from the Swedish Prescribed Drug Registry provided information on H. pylorieradication treatment, whereas information concerning newly developed gastric adenocarcinoma was retrieved from the Swedish Cancer Registry. The risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in individuals who had received H. pylorieradication treatment was compared with the background population of the corresponding age, sex and calendar year distribution, yielding standardised incidence ratios (SIRs) with 95% CIs.ResultsDuring the follow-up of 95 176 individuals who had received eradication treatment (351 018 person-years at risk), 75 (0.1%) developed gastric adenocarcinoma and 69 (0.1%) developed non-cardia gastric adenocarcinoma. The risk of gastric adenocarcinoma decreased over time after eradication treatment to levels below that of the corresponding background population. The SIRs were 8.65 (95% CI 6.37 to 11.46) for 1–3 years, 2.02 (95% CI 1.25 to 3.09) for 3–5 years and 0.31 (95% CI 0.11 to 0.67) for 5–7.5 years after eradication treatment. When restricted to non-cardia adenocarcinoma, the corresponding SIRs were 10.74 (95% CI 7.77 to 14.46), 2.67 (95% CI 1.63 to 4.13) and 0.43 (95% CI 0.16 to 0.93).ConclusionEradication treatment for H. pyloriseems to counteract the development of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in this Western population.

Published
2018
Full Text
View/download PDF

16. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus

Author

Fitzgerald, Rebecca C, primary, di Pietro, Massimiliano, additional, Ragunath, Krish, additional, Ang, Yeng, additional, Kang, Jin-Yong, additional, Watson, Peter, additional, Trudgill, Nigel, additional, Patel, Praful, additional, Kaye, Philip V, additional, Sanders, Scott, additional, O'Donovan, Maria, additional, Bird-Lieberman, Elizabeth, additional, Bhandari, Pradeep, additional, Jankowski, Janusz A, additional, Attwood, Stephen, additional, Parsons, Simon L, additional, Loft, Duncan, additional, Lagergren, Jesper, additional, Moayyedi, Paul, additional, Lyratzopoulos, Georgios, additional, and de Caestecker, John, additional

Published
2013
Full Text
View/download PDF

21. Increased risk of acute pancreatitis among tetracycline users in a Swedish population-based caseecontrol study.

Author

Ljung, Rickard, Lagergren, Jesper, Bexelius, Tomas S., Mattsson, Fredrik, and Lindblad, Mats

Subjects
*PANCREATITIS, *TETRACYCLINE, *PANCREATITIS treatment, *DRUG efficacy, *LOGISTIC regression analysis, *PUBLIC health, *DISEASE risk factors
Abstract

Objective To evaluate the suggested association between tetracycline and acute pancreatitis in a large pharmacoepidemiological study. Design The use of tetracycline in relation to the risk of acute pancreatitis was examined in a nationwide caseecontrol study of people aged 40e84 years between 2006 and 2008 in Sweden. The Swedish Patient Register was used to identify 6161 cases of firstepisode acute pancreatitis. The Register of the Total Population was used to randomly select 61 637 control subjects from the general population using frequencybased density sampling, matched for age, sex, and calendar year. Tetracycline use was defined as 'current', 'recent', 'past' or 'former' if the drug had been dispensed 0e30 days, 31e180 days, 181e365 days or 1e3½ years before the index date, respectively. The risk of acute pancreatitis was estimated by unconditional logistic regression, providing ORs with 95% CIs, adjusted for potential confounding factors. Results There was a 60% increased risk of acute pancreatitis among current users of tetracycline after adjustment for potential confounders (OR=1.6, 95% CI 1.2 to 2.1). There was no increased OR for any category of previous use. Conclusion Current use of tetracycline is associated with an increased risk of acute pancreatitis, verifying previous case reports. INSET: Significance of this study. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results